Question 1

What does Concord Biotech Ltd. look like financially right now?

Accepted Answer

Concord Biotech Ltd. is currently shown with a market value of ₹12.78K Cr. In FY25, reported sales were ₹1.20K Cr and net profit was ₹371.64 Cr. That gives investors a quick starting point: first check whether growth, margins, and cash flow are moving in the same direction before judging the stock only by price.

Question 2

Is Concord Biotech Ltd. growing sales and profit consistently?

Accepted Answer

Concord Biotech Ltd.'s latest annual sales growth is 0.00%, while net profit growth is 0.00%. When sales and profit grow together, quality of growth is usually better. If profit growth trails sales growth, it is worth checking margins, employee cost, finance cost, and tax rate in the P&L tab.

Question 3

How did Concord Biotech Ltd. perform in the latest quarter?

Accepted Answer

For December 2025 quarter, the available quarterly data shows sales of ₹277.77 Cr and net profit of ₹63.64 Cr. A single quarter should not be read in isolation; compare it with the previous quarter and the same quarter last year to separate seasonal movement from a real trend change.

Question 4

Are Concord Biotech Ltd.'s margins healthy?

Accepted Answer

Concord Biotech Ltd.'s latest operating margin is 44.26%, and net profit margin is 29.86%. That points to a business with reasonable profit retention after costs.

Question 5

Is Concord Biotech Ltd. efficient with shareholder capital?

Accepted Answer

Return on equity is 22.26%, while return on capital employed is 29.53%. A strong company generally earns good returns without taking excessive debt. Read ROE together with debt-to-equity and cash flow, because high leverage can make headline returns look better than the underlying business quality.

Question 6

Does Concord Biotech Ltd.'s valuation look expensive or reasonable?

Accepted Answer

Concord Biotech Ltd. trades at a P/E of 40.58, compared with an industry P/E of 32.10. Price-to-book is 9.67. A lower multiple is not automatically cheap, and a higher multiple is not automatically expensive; the right question is whether growth, margins, balance sheet strength, and cash generation justify the valuation.

Question 7

How strong is Concord Biotech Ltd.'s balance sheet?

Accepted Answer

Concord Biotech Ltd.'s debt-to-equity ratio is 0.00, current ratio is 3.74, and cash plus bank balance is ₹1.18 Cr. A cleaner balance sheet gives management more room during weak cycles; a stretched one makes cash flow and interest coverage more important.

Question 8

Is Concord Biotech Ltd. converting profit into cash?

Accepted Answer

Operating cash flow is ₹244.52 Cr, and free cash flow is ₹133.35 Cr. For fundamental investors, this is one of the most important checks. Profits backed by cash are generally more reliable than profits driven mainly by accounting accruals.

Question 9

How efficiently does Concord Biotech Ltd. manage working capital?

Accepted Answer

Receivable days are 158.66, inventory days are 72.89, and the cash conversion cycle is 197.17 days. Rising receivable days or a longer cash cycle can signal slower collections, even when reported revenue looks healthy.

Question 10

What does Concord Biotech Ltd.'s shareholding pattern indicate?

Accepted Answer

The latest shareholding data shows promoter holding at 44.08%, FII holding at 7.30%, and DII holding at 7.84%. Changes in institutional and promoter ownership are useful signals, but they should be read alongside earnings delivery and valuation rather than used as a standalone buy or sell trigger.

Question 11

Who are Concord Biotech Ltd.'s listed peers?

Accepted Answer

Concord Biotech Ltd. is shown alongside peers such as Cipla Ltd., Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd.. Peer comparison is useful for checking whether valuation, margins, ROE, and growth are company-specific strengths or simply sector-wide conditions.

Question 12

What should investors monitor before making a decision on Concord Biotech Ltd.?

Accepted Answer

For Concord Biotech Ltd., the most useful checklist is simple: sales growth, margin trend, ROE/ROCE, debt-to-equity, operating cash flow, free cash flow, and valuation versus peers. If these indicators improve together, the investment case becomes stronger. If they diverge, the stock needs deeper work before any decision.

Question 13

Does Concord Biotech Ltd. pay meaningful dividends?

Accepted Answer

Concord Biotech Ltd.'s current dividend yield is 0.72%. Dividend yield should be read with payout ratio and cash flow. A yield backed by free cash flow is more durable than a yield funded by balance-sheet stress or one-off income.

Question 14

How is Concord Biotech Ltd. allocating capital?

Accepted Answer

Concord Biotech Ltd.'s investing cash flow is ₹-159.99 Cr, while financing cash flow is not available in the current dataset. This helps investors see whether cash is going into expansion, debt reduction, dividends, buybacks, or funding needs.

Question 15

Is Concord Biotech Ltd. reinvesting enough for future growth?

Accepted Answer

Capital spending and investments should be compared with revenue growth and ROCE. If Concord Biotech Ltd. can reinvest while keeping ROCE near 29.53%, growth is more valuable. If reinvestment rises while returns fall, investors should ask whether capital allocation quality is weakening.

Question 16

Is Concord Biotech Ltd.'s debt level risky?

Accepted Answer

Concord Biotech Ltd.'s debt-to-equity ratio is 0.00, and total debt is ₹1.61 Cr. Debt becomes more concerning when interest coverage weakens, cash flow turns negative, or current liabilities grow faster than current assets.

Question 17

Can Concord Biotech Ltd. service its interest cost comfortably?

Accepted Answer

Interest coverage is 476.53 times. Higher coverage gives a company more breathing room in weak markets. If coverage is not available or looks low, review finance cost trends in the P&L and cash flow from operations.

Question 18

What liquidity numbers matter most for Concord Biotech Ltd.?

Accepted Answer

The current ratio is 3.74 and quick ratio is 4.87. These ratios show short-term financial flexibility, but investors should also check receivable days and operating cash flow to understand real liquidity.

Question 19

What should investors compare in Concord Biotech Ltd.'s quarterly results?

Accepted Answer

For quarterly review, compare sales, net profit, margin, EPS, and finance cost against both the previous quarter and the same quarter last year. For Concord Biotech Ltd., the latest quarter shows sales of ₹277.77 Cr and net profit of ₹63.64 Cr.

Question 20

Is Concord Biotech Ltd.'s quarterly EPS improving?

Accepted Answer

Concord Biotech Ltd.'s latest adjusted EPS is ₹6.08. EPS should be checked with share count and one-off items. Rising EPS with stable margins is generally better quality than EPS growth driven only by lower tax or exceptional gains.

Question 21

Why should one quarter not decide the view on Concord Biotech Ltd.?

Accepted Answer

One quarter can be affected by seasonality, market volumes, input costs, or accounting timing. For Concord Biotech Ltd., the better approach is to watch a series of quarters and confirm whether sales, profit, cash flow, and working capital are telling the same story.

Question 22

How should Concord Biotech Ltd. be compared with peers?

Accepted Answer

Compare Concord Biotech Ltd. with Cipla Ltd., Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd. on P/E, revenue growth, ROE, debt, and free cash flow. A premium valuation is easier to justify when the company also has better growth, cleaner cash generation, or stronger return ratios.

Question 23

What can make Concord Biotech Ltd. deserve a higher valuation?

Accepted Answer

Concord Biotech Ltd. can deserve a higher multiple if growth is durable, ROE remains strong, free cash flow improves, and debt risk stays controlled. If those inputs weaken, a high P/E can quickly become harder to defend.

Question 24

What can make Concord Biotech Ltd. look cheap but still risky?

Accepted Answer

A lower P/E can still be risky if earnings are cyclical, cash flow is weak, debt is rising, or margins are under pressure. For Concord Biotech Ltd., valuation should be read together with sales growth of 0.00%, ROE of 22.26%, and free cash flow of ₹133.35 Cr.

Question 25

Is promoter pledging a concern for Concord Biotech Ltd.?

Accepted Answer

Promoter pledge is 0.00%. High pledge can increase risk during market corrections. A low or zero pledge is cleaner, but it still needs to be viewed with promoter holding trend and business performance.

Question 26

Are institutions increasing or reducing exposure to Concord Biotech Ltd.?

Accepted Answer

Latest FII holding is 7.30% and DII holding is 7.84%. Institutional movement can show market confidence, but it is best used as confirmation after checking earnings, valuation, and cash flow.

Question 27

What governance signals should be watched in Concord Biotech Ltd.?

Accepted Answer

Watch promoter holding, pledge, related-party disclosures, auditor remarks, debt changes, and cash conversion. Governance risk often shows up first in balance-sheet quality and cash flow, not only in headline profit.

Question 28

Is Concord Biotech Ltd. better suited for growth or value investors?

Accepted Answer

Concord Biotech Ltd. can be assessed by both styles. Growth investors should focus on sales growth, quarterly momentum, and reinvestment quality. Value investors should focus on valuation versus peers, cash flow, debt, and margin durability.

Question 29

What are the main risks investors should track for Concord Biotech Ltd.?

Accepted Answer

The main risks to track are slowing sales growth, margin compression, weak free cash flow, rising debt, higher receivable days, and expensive valuation. These risks matter more when several appear together rather than in isolation.

Question 30

What is a practical checklist before buying Concord Biotech Ltd.?

Accepted Answer

Before taking a view on Concord Biotech Ltd., check five things: revenue growth, profit margin, ROE/ROCE, free cash flow, and valuation versus peers. If the numbers disagree, wait for more evidence instead of forcing a conclusion from one metric.

Concord Biotech Ltd. Financial Terminal

Analyst FAQ

Key facts used in answers

Market Cap

P/E Ratio

ROE

Dividend Yield

6PROS

4CONS

3Business Snapshot

3Profitability And Valuation

3Balance Sheet And Cash Flow

3Ownership And Investor Checks

3Dividends And Capital Allocation

3Debt Risk And Financial Safety

3Quarterly Trend Checks

3Peer Comparison And Valuation

3Governance And Ownership Quality

3Investor Strategy And Risk Checklist

Important Investment Disclaimer